Immutep Limited (IMMP): Firm Reports Positive Data from Trials

Core Insights - Immutep Limited (NASDAQ:IMMP) is recognized as a promising micro-cap stock by analysts [1] - The company reported positive results from clinical trials for its drug candidate eftilagimod alpha (efti), showing significant efficacy in treating soft tissue sarcoma and a high overall survival rate for lung cancer patients [2] - A Phase III trial for efti as a first-line treatment for advanced non-small cell lung cancer has successfully enrolled over 170 patients, surpassing the necessary amount for futility analysis [3] Company Overview - Immutep Limited is a biotechnology firm focused on developing novel immunotherapies related to Lymphocyte Activation Gene-3 for cancer and autoimmune diseases, based in Australia [4]